Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.6M
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-2.42M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$581K
-
Number of sells
-
-12
Significant Holders of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) as of Q4 2024
12 filings reported holding ENSC - Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 19.6M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (0 shares), VANGUARD GROUP INC (0 shares), GEODE CAPITAL MANAGEMENT, LLC (0 shares), Cerity Partners LLC (0 shares), RENAISSANCE TECHNOLOGIES LLC (0 shares), Tower Research Capital LLC (TRC) (0 shares), Anson Funds Management LP (0 shares), SABBY MANAGEMENT, LLC (0 shares), UBS Group AG (0 shares), and HRT FINANCIAL LP (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.